Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men
Top Cited Papers
- 12 September 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (11), 1011-1022
- https://doi.org/10.1056/nejmoa1206168
Abstract
Current approaches to diagnosing testosterone deficiency do not consider the physiological consequences of various testosterone levels or whether deficiencies of testosterone, estradiol, or both account for clinical manifestations. We provided 198 healthy men 20 to 50 years of age with goserelin acetate (to suppress endogenous testosterone and estradiol) and randomly assigned them to receive a placebo gel or 1.25 g, 2.5 g, 5 g, or 10 g of testosterone gel daily for 16 weeks. Another 202 healthy men received goserelin acetate, placebo gel or testosterone gel, and anastrozole (to suppress the conversion of testosterone to estradiol). Changes in the percentage of body fat and in lean mass were the primary outcomes. Subcutaneous- and intraabdominal-fat areas, thigh-muscle area and strength, and sexual function were also assessed. The percentage of body fat increased in groups receiving placebo or 1.25 g or 2.5 g of testosterone daily without anastrozole (mean testosterone level, 44±13 ng per deciliter, 191±78 ng per deciliter, and 337±173 ng per deciliter, respectively). Lean mass and thigh-muscle area decreased in men receiving placebo and in those receiving 1.25 g of testosterone daily without anastrozole. Leg-press strength fell only with placebo administration. In general, sexual desire declined as the testosterone dose was reduced. The amount of testosterone required to maintain lean mass, fat mass, strength, and sexual function varied widely in men. Androgen deficiency accounted for decreases in lean mass, muscle size, and strength; estrogen deficiency primarily accounted for increases in body fat; and both contributed to the decline in sexual function. Our findings support changes in the approach to evaluation and management of hypogonadism in men. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00114114.)This publication has 52 references indexed in Scilit:
- Length of the human androgen receptor glutamine tract determines androgen sensitivity in vivoMolecular and Cellular Endocrinology, 2011
- Loss of Hip BMD in Older Men: The Osteoporotic Fractures in Men (MrOS) StudyJournal of Bone and Mineral Research, 2009
- Age-related changes in total and regional fat distributionAgeing Research Reviews, 2009
- Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor‐αThe FASEB Journal, 2008
- Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral densityOsteoporosis International, 2008
- Sex steroids and sexual desire in a man with a novel mutation of aromatase gene and hypogonadismPsychoneuroendocrinology, 2005
- Body Fat Distribution and Insulin Resistance in Healthy Asian Indians and CaucasiansJournal of Clinical Endocrinology & Metabolism, 2001
- Androgen Replacement Therapy in the Aging Male--A Critical EvaluationJournal of Clinical Endocrinology & Metabolism, 2001
- Quantitative Assessment of Cross-Sectional Muscle Area, Functional Status, and Muscle Strength in Men with the Acquired Immunodeficiency Syndrome Wasting SyndromeJournal of Clinical Endocrinology & Metabolism, 1999
- Relationship of Serum Sex Steroid Levels and Bone Turnover Markers with Bone Mineral Density in Men and Women: A Key Role for Bioavailable EstrogenJournal of Clinical Endocrinology & Metabolism, 1998